Trial: 202008197

A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients

Phase

III (Cancer Control)

Principal Investigator

Oh, Stephen

Disease Site

Other Hematopoietic

Learn more about this study at: clinicaltrials.gov